Wolverine Stack Dosage Chart.

It depends entirely on the vendor, which is exactly why this is the most expensive mistake on this page. A vial listed as "BPC-157 10 mg / TB-500 10 mg" contains 20 mg of powder, 10 mg of each. A vial listed as "Wolverine Stack 10 mg" almost always means 10 mg total, so 5 mg of each. Same printed number, half the peptide. Before you add water, work out the total powder weight and the amount of each peptide inside it, because the calculator, the concentration and every unit count depend on the total. If the listing does not say, ask the vendor and do not guess.

Ten units, on a 20 mg blend vial mixed with 2 mL of bacteriostatic water. That gives 10,000 mcg/mL, and one unit on a U-100 syringe is 0.01 mL, so one unit is 100 mcg of blend. On a 1:1 vial that unit is 50 mcg of BPC-157 and 50 mcg of TB-500. Change the vial size or the water volume and every number changes: a 10 mg vial in the same 2 mL makes each unit 50 mcg of blend, so 1,000 mcg becomes 20 units, not 10. Always recalculate from the vial in front of you.

Separate vials, if you want each peptide dosed the way its own protocol says. BPC-157 convention is a small dose every day; TB-500 convention is a large dose twice a week. A fixed 1:1 blend cannot do both; whatever cadence you pick, one of the two peptides is off its usual schedule. Separate vials let you run BPC-157 at 250 mcg daily and TB-500 at 2.5 mg twice weekly, exactly as each chart specifies, and they let you stop one without stopping the other. The blend wins on convenience and on having one vial to mix instead of two. Neither arrangement has been compared to the other in a human study.

Because the blend is dosed to the BPC-157 side. BPC-157 is conventionally taken daily, so a 1:1 blend follows that cadence and the TB-500 comes along with it, spread across seven smaller injections instead of two large ones. At the standard tier that works out to 3.5 mg of TB-500 a week, which is close to the usual weekly total even though the pattern is different. Whether spreading it out matters is unknown; no study has compared dosing frequencies for TB-500 in humans, at any dose, by any route.

You overdose the BPC-157 side badly. A TB-500 chart says 2.5 mg twice weekly. Draw 2.5 mg out of a 1:1 blend and you have injected 1.25 mg of TB-500 (half of what you intended) plus 1.25 mg of BPC-157, which is five times the conventional 250 mcg dose. Try to fix the TB-500 shortfall by drawing 5 mg of blend and you are now injecting 2.5 mg of BPC-157 in one shot, ten times the usual dose. This is the single commonest error people make with blends, and it comes from reading a single-peptide number off a single-peptide chart and applying it to a vial holding two.

People do it routinely, and there is no published compatibility or stability study for the combination: not for the pre-blended vials, and not for drawing two reconstituted peptides into one barrel. If you are running separate vials, the cleaner approach is two injections, because it keeps the doses independent and means a problem with one vial does not contaminate the other. If you do combine them, draw them one after the other into the same syringe and inject immediately rather than letting the mixture stand.

Four to six weeks at the standard dose is the block almost every protocol uses, sometimes with a two to three week front-load at the higher dose first. That number is convention, not a studied duration. It happens to line up with two practical constraints: a 20 mg vial at 1,000 mcg a day lasts 20 days, and a reconstituted vial should be finished inside about 28 days because of the preservative in bacteriostatic water. So a typical run is one to two vials. Set an end date before you start rather than deciding week by week.

The combination has never been tested in humans. Neither has either component, for injury healing, by the subcutaneous route people actually use. Filtering PubMed for BPC-157 clinical trials returns zero published controlled trials; the human record is a Phase 1 study of oral tablets that posted no results, a 16-patient uncontrolled case series of intra-articular knee injections, and a Phase 2 trial for hamstring strain that is still recruiting. TB-500 itself (the Ac-LKKTETQ fragment) has no human trial at all; the human safety and pharmacokinetic data everyone quotes is for full-length recombinant thymosin β4 given intravenously, which is a different molecule by a different route.

Yes, both halves, and they are prohibited under different sections. BPC-157 falls under WADA category S0, unapproved substances, because it has no approval for human therapeutic use from any regulatory authority anywhere: prohibited at all times, in and out of competition. Thymosin β4 and its TB-500 fragment are covered as a prohibited growth factor. There is no therapeutic-use exemption available for a compound with no approved indication, and TB-500 metabolites have been characterised specifically for anti-doping detection in plasma and urine. If you are tested under the WADA code or any body that adopts it, this stack is disqualifying at any dose.